# Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout

> **NCT04875702** · PHASE4 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 650 (estimated)

## Conditions studied

- Gout

## Interventions

- **DRUG:** Allopurinol
- **DRUG:** Naproxen 250 MG
- **DRUG:** Colchicine 0.6 mg
- **DRUG:** Colchicine 1.2 mg
- **DRUG:** Naproxen 500 Mg
- **DRUG:** Prednisone 40 mg

## Key facts

- **NCT ID:** NCT04875702
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-22
- **Primary completion:** 2028-09-01
- **Final completion:** 2028-10-31
- **Target enrollment:** 650 (ESTIMATED)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04875702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04875702, "Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04875702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*